Home :: Kentucky Heart Foundation

The Kentucky Heart Foundation is a non-profit research institute dedicated to improving quality of life by reducing the devastating impact of cardiovascular disease in the tri-state area through research, education, prevention and early detection.

Click to Learn More
Education and screenings sponsored by the Kentucky Heart Foundation provide a platform for prevention and early detection of heart and vascular disease as well as early treatment. Education focuses on physicians, the public and staff.

Click to Learn More
Kentucky Heart Foundation focuses its research on introducing new and effective therapies to King’s Daughters Medical Center and to the region. By promoting research, we help answer clinical questions and optimize patient care today and into the future.

Click to Learn More

Latest News

Wed, February 24, 2010
KDMC Offers Free Screening at Waverly
King’s Daughters Medical Center, in cooperation with the Kentucky Heart Foundation (KHF), is offering a free screening to detect PAD. The screening will begin at 8:30 a.m. March 19 on the KDMC Mobile Health Unit at the Family Health Center, 227 Valleyview Drive, Waverly, Ohio.

Mon, February 22, 2010
Boyd and Greenup Counties Receive Grant to Tackle Childhood Obesity
Boyd and Greenup counties have been selected as one of only a handful of communities in the country to become part of Action Communities for Health, Innovation, and EnVironmental ChangE (ACHIEVE).

Mon, February 15, 2010
KDMC Sponsors Vascular Screening in Salyersville
King’s Daughters Medical Center, in cooperation with the Kentucky Heart Foundation (KHF), is offering a free screening to detect PAD. The screening will begin at 8:30 a.m. March 16 on the KDMC Mobile Health Unit at the Hope Clinc, 835 Parkway Drive, Salyersville, Ky.

Recently Added Trials

OptiVol Care Pathway

To compare monthly versus quarterly review of CardiacCompass Trends with OptiVol for initiation of clinical action.

APPRAISE 2

To determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome (ACS).

DAPT

To assess the effectiveness and sefety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing Percutaneous coronary intervention.

DETERMINE

To determine if Implantable Cardioverter Defibrillator therapy in combination with medical therapy in patients with an infarct size greater than or equal to 10 percent of the left ventricular mass improves long term survival compared to medical therapy alone.